Article Text

Download PDFPDF
Novel compound heterozygous variants in the NBAS gene in a child with osteogenesis imperfecta and recurrent acute liver failure
  1. Sowmya Krishnan1,
  2. Ankur Rughani1,
  3. Anne Tsai2 and
  4. Sirish Palle3
  1. 1Pediatrics, Section of Diabetes and Endocrinology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
  2. 2Pediatrics, Section of Genetics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
  3. 3Pediatrics, Section of Gastroenterology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
  1. Correspondence to Dr Sowmya Krishnan; sowmya-krishnan{at}ouhsc.edu

Abstract

Osteogenesis imperfecta (OI) consists of a group of genetically and phenotypically heterogeneous diseases characterised by bone fragility. Recent improvement in gene sequencing methods has helped us identify rare forms of OI that are inherited in an autosomal recessive manner. Paediatric endocrinology was consulted on a newborn girl with multiple fractures and wavy thin ribs noted on X-rays. In addition to the bone phenotype, she also has short stature and recurrent acute liver failure (ALF) episodes triggered by intercurrent illness. Whole exome sequencing revealed two novel compound heterozygous variants in neuroblastoma amplified sequence (NBAS) gene. NBAS gene codes for a protein that is involved in nonsense-mediated decay pathway and retrograde transport of proteins from Golgi to endoplasmic reticulum. Recognition of pathogenic variants in this gene as a rare cause of autosomal recessive OI and recurrent ALF has important therapeutic implications.

  • paediatrics (drugs and medicines)
  • calcium and bone
  • genetics

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors SK was involved in the initial work up, treatment and follow up of the child. She initiated the draft of the manuscript and data analysis. AR was involved in writing the manuscript, revision and editing manuscript. SP was the liver specialist taking care of this child and provided input on interpretation of data and treatment. AT is a geneticist and helped us in the interpretation of genetic test results and contributed to write the genetic aspect of the disease.

  • Funding This study was funded by National Institute of Health (U54GM104938, UG1OD024950).

  • Competing interests None declared.

  • Patient consent for publication Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.